Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone Sodium Phosphate

FDA-approved product (ointment, ophthalmic), marketed as Decadron, Dexacen-4, Dexacort and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Brain edema
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 66 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

    NCT02036502 · start 2014-02-14

    Registered record
    Registry ID
    NCT02036502
    Conditions
    Multiple Myeloma
    Interventions
    Pembrolizumab; Lenalidomide; Dexamethasone; Carfilzomib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-02-14
    Completion
    2020-03-19
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionPembrolizumab; Lenalidomide; Dexamethasone; Carfilzomib
    PhasePhase 1
    Registry statusTerminated

  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

    NCT02036424 · start 2014-01

    Registered record
    Registry ID
    NCT02036424
    Conditions
    Diabetic Macular Edema
    Interventions
    Ozurdex; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01
    Completion
    2015-08
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Macular Edema
    InterventionOzurdex; Bevacizumab
    PhasePhase 4
    Registry statusCompleted

  • Management of Pain in Lumbar Arthrodesis

    NCT04751175 · start 2013-07-04

    Registered record
    Registry ID
    NCT04751175
    Conditions
    Pain, Postoperative
    Interventions
    Ketamine; Dexamethasone; Physiologic saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-07-04
    Completion
    2025-12-31
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative
    InterventionKetamine; Dexamethasone; Physiologic saline
    PhasePhase 4
    Registry statusCompleted

  • Caffeic Acid Tablets as a Second-line Therapy for ITP

    NCT02351622 · start 2012-09

    Registered record
    Registry ID
    NCT02351622
    Conditions
    Immune Thrombocytopenia
    Interventions
    Caffeic acid; Dexamethasone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-12
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenia
    InterventionCaffeic acid; Dexamethasone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

    NCT01564537 · start 2012-08-01

    Registered record
    Registry ID
    NCT01564537
    Conditions
    Relapsed Multiple Myeloma; Refractory Multiple Myeloma
    Interventions
    Ixazomib; Lenalidomide; Dexamethasone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2022-02-08
    Enrolment
    722

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Multiple Myeloma; Refractory Multiple Myeloma
    InterventionIxazomib; Lenalidomide; Dexamethasone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

    NCT01526694 · start 2012-07

    Registered record
    Registry ID
    NCT01526694
    Conditions
    Multiple Myeloma
    Interventions
    Bendamustine; Thalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2017-04-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionBendamustine; Thalidomide; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO

    NCT01580020 · start 2012-05

    Registered record
    Registry ID
    NCT01580020
    Conditions
    Retinal Vein Occlusion
    Interventions
    RFB002; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-10
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Vein Occlusion
    InterventionRFB002; Dexamethasone
    PhasePhase 4
    Registry statusCompleted

  • Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome

    NCT00711841 · start 2011-07

    Registered record
    Registry ID
    NCT00711841
    Conditions
    HELLP Syndrome
    Interventions
    dexamethasone; Placebo; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-07
    Completion
    2019-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELLP Syndrome
    Interventiondexamethasone; Placebo; dexamethasone
    PhasePhase 4
    Registry statusTerminated

  • Ovarian Contribution to Androgen Production in Adolescent Girls

    NCT01421810 · start 2011-03-10

    Registered record
    Registry ID
    NCT01421810
    Conditions
    Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
    Interventions
    Dexamethasone; rhCG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2011-03-10
    Completion
    2025-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Obesity; Hyperandrogenism
    InterventionDexamethasone; rhCG
    PhaseNot applicable
    Registry statusUnknown

  • Methylprednisolone Replacement for Dexamethasone-induced Hiccup

    NCT01277731 · start 2010-07

    Registered record
    Registry ID
    NCT01277731
    Conditions
    Dexamethasone; Hiccup
    Interventions
    Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2010-07
    Completion
    2011-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDexamethasone; Hiccup
    InterventionMethylprednisolone
    PhaseNot applicable
    Registry statusWithdrawn

  • Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

    NCT01204307 · start 2010-01

    Registered record
    Registry ID
    NCT01204307
    Conditions
    Advanced Non-Squamous Non-Small Cell Lung Cancer
    Interventions
    Docetaxel/cisplatin; Pemetrexed/cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2015-06
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-Squamous Non-Small Cell Lung Cancer
    InterventionDocetaxel/cisplatin; Pemetrexed/cisplatin
    PhasePhase 2
    Registry statusCompleted

  • AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

    NCT01001091 · start 2009-12

    Registered record
    Registry ID
    NCT01001091
    Conditions
    Allergic Conjunctivitis
    Interventions
    AL-38583 ophthalmic solution; AL-38583 ophthalmic solution vehicle; Dexamethasone ophthalmic suspension, 0.1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-12
    Completion
    2010-04
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionAL-38583 ophthalmic solution; AL-38583 ophthalmic solution vehicle; Dexamethasone ophthalmic suspension, 0.1%
    PhasePhase 2
    Registry statusCompleted

  • Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

    NCT01091831 · start 2009-07

    Registered record
    Registry ID
    NCT01091831
    Conditions
    Multiple Myeloma
    Interventions
    Cyclophosphamide; Lenalidomide; Dexamethasone; Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-07
    Completion
    2024-07-01
    Enrolment
    389

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionCyclophosphamide; Lenalidomide; Dexamethasone; Melphalan
    PhasePhase 3
    Registry statusCompleted

  • New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma

    NCT00933673 · start 2009-06

    Registered record
    Registry ID
    NCT00933673
    Conditions
    Lymphoma
    Interventions
    L-asp, DXM, IFO, VP-16, DDP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2012-06
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionL-asp, DXM, IFO, VP-16, DDP
    PhasePhase 2
    Registry statusUnknown

  • A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients

    NCT00733083 · start 2008-09

    Registered record
    Registry ID
    NCT00733083
    Conditions
    Post Tonsillectomy Pain
    Interventions
    0,1 mg/kg of oxycodone; Morphine 0,1 mg/kg; Dexamethasone 0,5 mg/kg; NaCl 0,9%
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2008-09
    Completion
    2010-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Tonsillectomy Pain
    Intervention0,1 mg/kg of oxycodone; Morphine 0,1 mg/kg; Dexamethasone 0,5 mg/kg; NaCl 0,9%
    PhaseNot applicable
    Registry statusUnknown